For descriptions and updates on the vaccines currently in Phase III clinical trials, check out The New York Times Coronavirus Vaccine Tracker or the VaC COVID-19 vaccine tracker.
Explore This Issue
ACEP Now: Vol 39 – No 11 – November 2020References
- Fontanet A, Cauchemez S. COVID-19 herd immunity: where are we? Nat Rev Immunol. 2020;20(10):583-584.
- Parker EPK, Shrotri M, Kampmann B. Keeping track of the SARS-CoV-2 vaccine pipeline. Nat Rev Immunol. 2020;20(11):650.
- What are the benefits of flu vaccination? Centers for Disease Control and Prevention website. Available at: https://www.cdc.gov/flu/prevent/vaccine-benefits.htm. Accessed Oct. 29, 2020.
- Calina D, Sarkar C, Arsene AL, et al. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development [published online ahead of print Oct. 1, 2020]. Immunol Res. doi:10.1007/s12026-020-09154-4.
- WHO target product profiles for COVID-19 vaccines. World Health Organization website. Available at: https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines. Accessed Oct. 29, 2020.
- Ada GL. The ideal vaccine. World J Microbiol Biotechnol. 1991;7(2):105-109.
- Collins FS. Reengineering translational science: the time is right. Sci Transl Med. 2011;3(90):90cm17.
- Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586(7827):113-119.
- Overview, history, and how the safety process works. Centers for Disease Control and Prevention website. Available at: https://www.cdc.gov/vaccinesafety/ensuringsafety/history/index.html. Accessed Oct. 29, 2020.
- Begum J, Mir NA, Dev K, et al. Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development [published online ahead of print Aug. 20, 2020]. Transbound Emerg Dis. doi:10.1111/tbed.13804.
- Jeyanathan M, Afkhami S, Smaill F, et al. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615-632.
- Subbaraman N. Who gets a COVID vaccine first? Access plans are taking shape. Nature. 2020;585(7826):492-493.
- U.S. Department of Health and Human Services, Health Resources and Services Administration, National Center for Health Workforce Analysis. Sex, Race, and Ethnic Diversity of U.S. Health Occupations (2011-2015), Rockville, Maryland. 2017.
Dr. Niforatos is an emergency medicine resident at the Johns Hopkins School of Medicine in Baltimore and research editor of Brief19.com. Follow him on Twitter @ReverendofDoubt and follow Brief19 @Brief_19.
Pages: 1 2 3 | Single Page
2 Responses to “Overview of COVID-19 Vaccine Research”
November 17, 2020
Arthur L. DiskinAnother interesting candidate is an oral vaccine from Vaxart. End of Phase 1. They are also developing oral flu and norovirus vaccines. Obviously, the logistics of an oral vaccine, especially in places like Africa where refrigeration would be a challenge would be amazing
December 15, 2020
George Ellis, MD,FACEPReturn to March for appropriate evaluation of specific information relevant to the symptoms was lacking some of the most important presentations. Ie: hypoxemia seemingly out of proportion to appearance, loss of the sense of smell and/or taste which is more likely to be seen in younger patients.